Get my own profile
Public access
View all26 articles
1 article
available
not available
Based on funding mandates
Co-authors
- Bernd KuhnF. Hoffmann-La RocheVerified email at roche.com
- Rainer E. MartinF. Hoffmann-La Roche LtdVerified email at roche.com
- Herbert WaldmannMax-Planck-Institut DortmundVerified email at mpi-dortmund.mpg.de
- Roger SchibliETH Zurich and Paul Scherrer Institute, SwitzerlandVerified email at pharma.ethz.ch
- Kenneth AtzAI Scientist at Roche | PhD AI/ML ETH ZürichVerified email at ethz.ch
- Dr. Franz SchulerF. Hoffmann-La Roche Ltd.Verified email at roche.com
- Markus G. RudolphF. Hoffmann-La Roche, Therapeutic ModalitiesVerified email at roche.com
- Marc NazareGroup leader, Leibniz-Forschungsinstitut für Molekulare (FMP)Verified email at fmp-berlin.de
- Mario van der SteltLeiden UniversityVerified email at chem.leidenuniv.nl
- Robert Narquizian, PhD, MBAHarvard University ; Glasgow university; London Business School, Roche; LillyVerified email at eccogene.com
- Pal PacherNational Institutes of Health, BethesdaVerified email at mail.nih.gov
- Dmitry VeprintsevProfessor of Molecular and Cellular Pharmacology, University of NottinghamVerified email at nottingham.ac.uk
- David F. NippaScientist @ RocheVerified email at roche.com
- Gisbert SchneiderETH ZurichVerified email at ethz.ch
- Yingfang HePhD candidate, ETH ZurichVerified email at pharma.ethz.ch
- Dr David Andrew SykesUniversity of NottinghamVerified email at nottingham.ac.uk
- Thais GazziETH ZurichVerified email at org.chem.ethz.ch
- Laura HeitmanFull Professor of Molecular PharmacologyVerified email at lacdr.leidenuniv.nl
- Roman C. SarottSNSF Postdoctoral Fellow, Stanford UniversityVerified email at stanford.edu
- Arne RuferF. Hoffmann-La Roche LtdVerified email at roche.com